 |
 | Writing and Filling a Prescription |
| |  | Guidelines for Substitution of a Different Formulation for a Prescribed Drug |
| | | Dispensing the Appropriate Capsule Combination for the Daily Dose of Temozolomide |
| | | Criteria for an Accurate Prescription of a Nebulized Bronchodilator |
| | | Dispensing the Appropriate Tablet Combination for the Daily Dose of Xeloda (Capecitabine) |
| | | Dispensing the Appropriate Number of Capsules of Succimer for Chelating Heavy Metals |
| | | Determining the Appropriate Dose of Sevelamer Hydrochloride to Control Serum Inorganic Phosphorus Levels in Patients with End Stage Renal Failure |
| | | Dispensing Sufficient Medication to Fill a Prescription |
| | | Amount of Cream or Ointment to Dispense for Topical Skin Application |
| | | Criteria for a Valid Prescription |
| | | Determining the Price to Charge for a Prescription |
| | | Calculation of the Weight of a Drug Compound to Dispense to Deliver a Target Dose of the Active Drug Moiety |
| | | Food and Drug Administration (FDA) Rules for Importation of an Unapproved Drug |
| | | Converting a Patient from Intravenous to Oral Drug Administration |
| | | Dispensing Sufficient Oseltamivir to Treat a Patient for Influenza |
| | | Reducing the Risk of Forged or Altered Prescriptions |
| | | Dispensing Sufficient Voriconazole (Vfend) for Intravenous Infusion |
| | | Dosing Nelfinavir mesylate (Viracept) for Oral Therapy in a Child |
| | | Predictors of Miller et al Identifying a Patient with a Chronic Disease Who Comes to the Emergency Department for a Drug Refill |
| Evaluation of a Patient's Ability to Take Medication |
| |  | Patient Assessment and Instruction in the Use of an Inhaler |
| | | Score of Ruscin and Semla for Evaluating a Patient's Ability to Perform Tasks Associated with Taking Tablets or Pills |
| | | When Rectal Administration of a Drug Should Be Considered |
| Formulary Management |
| | | Identification of High Risk Medications |
| | | Schedules for Controlled Substances |
| | | Scale of Nutt et al for Assessing the Harm of a Drug's Misuse Potential |
| Evaluation of Drug Therapy Regimens |
| | | General Rules for Treatment of a Chronic Condition from the International Consensus Guidelines for the Therapy of Idiopathic Pulmonary Fibrosis |
| | | Criteria for Unlabeled Use of a Medication |
| | | Troubleshooting the Failure of a Patient to Respond to a Medication |
| | | Clinical Utility Score of Kain |
| | | Total Cumulative Drug Exposure Over Time |
| | | Reasons Why an Antibiotic May Be Prescribed When Unnecessary |
| | | 1997 Beers Diagnosis Independent Criteria to Identify Potentially Inappropriate Drug Use In an Elderly Patient |
| Patient Education about Drug Regimens |
| | | A Checklist for Informing the Patient About a New Medication |
| | | The MedTake Test for Determining a Patient's Familiarity with Medications |
| | | A Patient Questionnaire Before Using Imitrex Nasal Spray for Migraine Headaches |
| Equivalent Drug Dosing |
| | | Dosing a Drug With an Additional Side Chain (Fosphenytoin and Phenytoin Equivalents) |
| | | Effects of Hydration on Drug Dosage |
| | | Dosing a Drug Formulated as a Salt |
| | | Equivalent Anti-Inflammatory Oral or Intravenous Corticosteroid Dose |
| | | Equivalent Narcotic (Equianalgesic) Drug Doses |
| | | Converting a Patient with ADHD to Extended Release Methylphenidate |
| | | Converting a Patient from Depakote to the Extended Release (ER) Formulation |
| | | FDA Criteria for Therapeutic Equivalence Between Two Drug Preparations |
| | | Converting a Patient Taking Intravenous Immune Globulin to Subcutaneous Immune Globulin (SCIG, Vivaglobin) |
| | | Equivalent Doses of Theophylline and Related Methylxanthines |
| Pain Medications |
| | | Indications for Using Parenteral Morphine for Control of Severe Pain |
| | | Method of Mercadante et al for Titrating Intravenous Morphine in a Patient with Severe Cancer Pain with Immediate Conversion to Oral Dosing |
| | | Method of Nelson et al for Administration of Parenteral Morphine for a Patient with Severe Cancer Pain |
| | | Method of Indelicato and Portenoy for Opioid Rotation in a Patient with Refractory Cancer Pain |
| | | Conversion of a Patient to Oral Oxycontin According to the Physicians' Desk Reference (PDR) |
| | | Management of Acute Pain in a Substance Abuser |
| | | Dosing Tylenol (Acetaminophen) in Children |
| | | Calculating the Aspirin Conversion Factor (ACF) for a Salicylate |
| | | Calculating the Aspirin Equivalent Dose (AED) for a Salicylate |
| | | Risk Factors for Opioid Toxicity in a Patient Being Treated for Pain |
| | | Clinical Findings of Opioid Toxicity in a Patient Being Treated for Pain |
| | | Features Suggestive of Drug Seeking Behavior in a Patient |
| | | Risk Factors of Ives et al for Opioid Misuse in a Patient with Chronic Pain |
| | | Patient Agreement with the Physician for the Use of Opioid or Other Controlled Substances |
| | | Contraindications for the Use of a Fentanyl Transdermal Patch in a Patient with Pain |
| | | Factors Associated with Toxic Symptoms in a Patient Taking Extended Release Oxymorphone |
| | | Opioid Induced Hyperalgesia (OIH) |
| Herbs and Alternative Medicines |
| | | Guidelines of Huxtable for Reducing the Risk of Herbal Use |
| | | Precautions for the Safe Use of Ephedrine and Related Alkaloids |
| | | Food and Drug Administration (FDA) Criteria for Determining if a Herb or Food Supplement Claims Use in a Disease |
| | | Complications Associated with Fish Oil Therapy |
| | | WHO Guidelines for Good Agricultural and Collection Practices (GACP) for Medicinal Plants: Harvesting the Plant |
| FDA Categories of Drugs for Use in Pregnancy |
| | | FDA Categories of Drugs for Use in Pregnancy |
| Cost Saving Techniques |
| | | Splitting Pills and Tablets |
| | | Maximal Use of Liquid Drug in Vials |
| | | Issues Affecting Outcome in Insurance Company Directed "Brown Bagging" of Chemotherapeutic Agents |
| Medication and Prescription Errors |
| | | Prevention of Prescription Errors for Controlled Substances |
| | | Prescription Abbreviations Associated with Dosage Errors |
| | | The National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) Categories for Medication Errors |
| | | Risk Factors for Medication Errors Identified by the American Society of Hospital Pharmacists (ASHP) |
| | | Risk Factors in Pharmacy Practice on Dispensing Errors |
| | | Reasons for Prescription Medications Being Wasted in Geriatric Outpatients |
| | | Risk Factors of Fialova et al for Inappropriate Medication Use in Elderly European Home Care Patients |
| | | Risk Factors Shi et al for a Patient to Inappropriately Use Over-the-Counter Phenazopyridine (Pyridium) |
| | | Types of Drug Diversion for a Controlled Substance |
| | | Classification of Manchikanti for Troubled Providers Who Write Presciptions for Controlled Substances |
| | | Recommendations of Argo et al for Reducing Serious Medication Errors |
| | | Prevention of Medication Errors in the Use of Drug Look-Alikes |
| | | Ways In Which a Patient May Accumulate a Large Supply of a Prescription Drug |
| | | Recommendations of Koren and Haslam for Reducing Tenfold and Other Dose Calculation Errors |
| Patient Drug Self-Administration |
| | | Selection of Sites for Self-Injection of Interferon-beta |
| | | Safety Guidelines for Patients Taking Chemotherapy Agents at Home |
| | | Intracavernosal Injection of Prostaglandin E1 by a Man with Erectile Dysfunction |
| | | Anticoagulation Using Subcutaneous Injection of Enoxaparin (Low Molecular Weight Heparin) |
| | | Intranasal Administration of Desmopressin Acetate |
| | | Subcutaneous Injection of Insulin |
| | | Testosterone Buccal System with Mucoadhesive (Striant) |
| | | General Instructions for Handling a Transdermal Therapeutic System (Drug Patch) |
| | | Instructions for Withdrawal of a Parenteral Dose from a Drug Vial |
| | | Instillation of Ofloxacin Otic Drops for an Ear Infection |
| | | General Instructions for a Patient Taking an Oral Bisphosphonate for Osteoporosis |
| | | Instructions for Application of a Vaginal Cream |
| | | Instructions for Administration of a Nasal Spray |
| | | Administration of Diazepam Rectal Gel (Diastat AcuDial) to a Patient with a Seizure Disorder |
| | | Handling Problems Associated with Self-Injections |
| | | Instructions for Handling a Potentially Toxic Medication at Home |
| Storage and Replacement of Medications |
| | | Estimating Shelf-Life of a Drug Using the Q10 Method |
| | | Assessing Drug Potency After the Expiration Date |
| | | Methods to Detect Thawing of a Frozen Solution |
| | | Evaluation of a Medication for Deterioration After Exposure to the Environment |
| | | Problems Associated with the Freezing of Medications |
| Suppositories |
| | | The Density Factor Method for Preparing a Medicated Suppository |
| | | The Occupied Volume Method for Preparing a Medicated Suppository |
| Emulsions and Surfactants |
| | | Amount of Surfactant Required to Emulsify an Oil |
| | | Blending Two Surfactants to Achieve a Mixture with a Specific Hydrophile-Lipophile Balance (HLB) |
| Solubility and Bioavailability of Drug Preparations |
| | | Solubility of a Drug That is the Salt of an Acid |
| | | Determining the pH to Dispense a Solution of a Salt of an Acidic Drug for Optimum Solubility |
| | | Dose Solubility Ratio |
| | | Descriptive Terms for Solubility of a Solute in a Solvent |
| | | Biopharmaceutical Classification Scheme (BCS) for Bioavailability of a Drug After Oral Administration |
| Placebo and Nocebo Effects |
| | | Placebo and Nocebo Effects |
| Special Precautions During Preparation and Handling of Medications |
| | | NIH Recommendations for Preparation of Parenteral Antineoplastic Agents |
| | | NIH Recommendations for Administration of Parenteral Antineoplastic Agents |
| | | Risk Level Classification of the American Society of Health-System Pharmacists (ASHP) for Pharmacy-Prepared Sterile Products |
| | | Monitoring a Person Who Handles or Administers Parenteral Antineoplastic Agents |
| Packaging of Medications |
| | | Problems Caused by Child-Resistant Packaging for the Elderly |
| | | Problems Caused by Tamper-Resistant Packaging for the Elderly |
| | | Measuring the Moisture Permeability of a Container for Multiple Tablets or Capsules |
| | | Indications of Tenenbein for Selecting Unit Dose Packaging of a Medication |
| Tablets and Capsules |
| | | Testing a Tablet's Durability in a Friabilator |
| | | Crushing Tablets and Mixing the Powder with Food for Drug Administration to Adolescents and Adults |
| | | Crushing Tablets or Capsules for Drug Administration to an Infant |
| | | Hard Capsule Size and Volume |
| Aerosols |
| | | Estimating the Vapor Pressure of a Mixture of Two Liquified Gas Propellants |
| | | Determining the Ratio of Two Liquified Gas Propellants to Deliver a Specific Vapor Pressure for an Aerosol |
| | | Effect of Particle Size on the Site of Deposition in the Respiratory Tract |
| Administration of Chimeric Antibodies and Targeted Therapies |
| | | Predicting a Medically Significant Reaction in Pediatric Patients Receiving an Infusion of Infliximab |
| | | Algorithm of Sandborn and Hanauer for Administering Infliximab to a Patient with Crohn's Disease |
| | | When to Suspect the Formation of Anti-Infliximab Antibodies in a Patient |
| | | Contraindications for the Use of Infliximab (Antibody to Tumor Necrosis Factor alpha) |
| Filters and Filtration |
| | | Decision Tree of McKinnon and Avis for Selection of a Filter System for Pharmaceutical Preparation |
| Dosing of Respiratory Medications |
| | | Dosing and Administration of Pulmonary Surfactant (Survanta, Beractant) |
| | | Determining the Infusion of Epoprostenol Sodium (Flolan) for a Patient with Pulmonary Hypertension |
| | | Dosing Xolair (Omalizumab) in a Patient with Asthma |
| Dosing of Cardiac Drugs |
| | | Determining the Dose of Sotalol in an Adult Patient to Control Atrial Fibrillation or Flutter |
| | | Determining the Dose of Sotalol in a Pediatric Patient to Control Atrial Fibrillation or Flutter |
| | | Maintenance Dosing of an Adult Patient with Atrial Fibrillation or Flutter Receiving Sotalol |
| | | Determining the Regimen of Integrilin (Eptifibatide) for a Patient with an Acute Coronary Syndrome |
| | | Adjusting the Dose of Eplerenone (Inspira) for a Patient with Congestive Heart Failure Based on the Serum Potassium |
| Dosing of Neurologic Drugs |
| | | Precautions in Dosing Mitoxantrone for Patients with Multiple Sclerosis |
| Prescribing and Dispensing Drugs with Teratogenic Potential |
| | | The STEPS (System for Thalidomide Education and Prescribing Safety) Program of Celgene Corporation for Thalidomide |
| | | The SMART (System to Manage Accutane Related Teratogenicity) Program of Roche Pharmaceuticals for Isotretinoin |
| | | Precautions in the Exposure to Ribavirin in a Patient of Reproductive Age |
| Ophthalmic Preparations |
| | | Determining the Amount of Sodium Chloride to Add to an Ophthalmic Solution to Make It Isotonic With Normal Tears |
| | | Depot Method for the Application of Topical Ophthalmologic Medication |
| | | Number of Drops of an Ophthalmologic Medication to Apply |
| Topical Preparations (Ointments, Creams. Pastes, Etc.) |
| | | Criteria for an Ideal Preservative in a Topical Preparation |
| | | Method of Application for a Cream or Ointment |
| Drug Absorption |
| | | Rule of 5 by Lipinski et al for Identifying a Drug with Poor Oral Absorption |
| | | Oral Absorption of an Azole for Antifungal Therapy in a Patient with Hypochlorhydria or Achlorhydria |
| Inhalers and Nebulized Medications |
| | | Determining the Amount of Medication Remaining in a Metered-Dose Inhaler Canister |
| | | Estimating the Number of Days Left for a Metered-Dose Inhaler Canister Based on Daily Usage Pattern |
| | | Dosage Preparation for Continuous Bronchodilator Therapy (CBT) Delivered by a Nebulizer |
| Injectable Formulations |
| | | Recommended Excess Volume for an Injectable Preparation |
| | | USP/NF Guidelines for Testing Injectable Preparations for Particulate Matter |
| Counterfeit Drugs |
| | | Risk of Buying a Counterfeit Drug |
| Advice to Travelers for Carrying Medications and Administration Supplies |
| | | Advice to Travelers for Carrying Medications and Administration Supplies |
| Factors Affecting Drugs Administered by Intravenous Infusion |
| | | Drugs That Are Absorbed Out of the Infusion Solution Onto the Infusion Set |
| Using Pharmacy Data to Monitor Patients |
| | | Drug Refill Gap |
| | | Medication Possession Ratio (MPR) |
| Dosing Gastrointestinal Medications |
| | | Dosing Imodium (Loperamide HCl) |
| Guidelines for Donating Drugs During a Disaster |
| | | Guidelines for Donating Drugs During a Disaster |
| Endocrine and Hormone Preparations |
| | | Dosing of Levothyroxine Sodium for a Pediatric Patient with Hypothyroidism |
| | | Dosing Zemplar (Paricalcitol) Capsules for a Patient with Secondary Hyperparathyroidism in Chronic Kidney Disease |
| | | Complications Associated with Long-Term Hormone Implants |
| Solutions of Ethyl Alcohol (Ethanol) |
| | | Preparation of a Diluted Alcohol Solution (Vol/Vol) from 94.9% Alcohol |
| Transdermal Formulations |
| | | Properties of a Medication Suitable for Transdermal Administration |
| | | Ways to Enhance Absorption of a Drug After Transdermal Administration |
| | | Impact of Temperature on Absorption from a Transdermal Patch |
| Drug Therapy Discontinuation |
| | | Possible Consequences of Drug Therapy Discontinuation |
| Pyrogen Testing |
| | | Reasons for Failing to Detect a Pyrogen in a Pharmaceutical Preparation |
| | | USP Rabbit Pyrogen Test |
| |
| TOP |